KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Deferred Taxes: 2018-2025

Historic Deferred Taxes for Xenon Pharmaceuticals (XENE) over the last 7 years, with Sep 2025 value amounting to -$701,000.

  • Xenon Pharmaceuticals' Deferred Taxes fell 117.70% to -$701,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$10.7 million, marking a year-over-year decrease of 2266.37%. This contributed to the annual value of -$8.9 million for FY2024, which is 2935.62% down from last year.
  • As of Q3 2025, Xenon Pharmaceuticals' Deferred Taxes stood at -$701,000, which was down 312.35% from -$170,000 recorded in Q2 2025.
  • Xenon Pharmaceuticals' 5-year Deferred Taxes high stood at $403,000 for Q1 2024, and its period low was -$8.6 million during Q4 2024.
  • For the 3-year period, Xenon Pharmaceuticals' Deferred Taxes averaged around -$1.0 million, with its median value being -$224,000 (2023).
  • As far as peak fluctuations go, Xenon Pharmaceuticals' Deferred Taxes soared by 2,766.67% in 2022, and later tumbled by 4,206.00% in 2024.
  • Xenon Pharmaceuticals' Deferred Taxes (Quarterly) stood at $346,000 in 2021, then crashed by 98.55% to $5,000 in 2022, then tumbled by 4,100.00% to -$200,000 in 2023, then tumbled by 4,206.00% to -$8.6 million in 2024, then slumped by 117.70% to -$701,000 in 2025.
  • Its Deferred Taxes stands at -$701,000 for Q3 2025, versus -$170,000 for Q2 2025 and -$1.2 million for Q1 2025.